Anticancer perspectives of monocarbonyl analogs of curcumin: A decade (2014-2024) review.
Arch Pharm (Weinheim)
; 357(9): e2400197, 2024 Sep.
Article
em En
| MEDLINE
| ID: mdl-38895952
ABSTRACT
Monocarbonyl analogs of curcumin (MACs) represent structurally modified versions of curcumin. The existing literature indicates that MACs exhibit enhanced anticancer properties compared with curcumin. Numerous research articles in recent years have emphasized the significance of MACs as effective anticancer agents. This review focuses on the latest advances in the anticancer potential of MACs, from 2014 to 2024, including discussions on their mechanism of action, structure-activity relationship (SAR), and in silico molecular docking studies.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Curcumina
/
Simulação de Acoplamento Molecular
/
Antineoplásicos
Limite:
Animals
/
Humans
Idioma:
En
Revista:
Arch Pharm (Weinheim)
Ano de publicação:
2024
Tipo de documento:
Article